ClinicalTrials.govpublic full text
Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes
metastatic colorectal cancer (mcrc), colorectal neoplasms, refractory metastatic colorectal cancer, hydroxychloroquine, regorafenib, kras mutation, nras mutation, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 879408
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.